Corporate Presentation

INDOCO REMEDIES LTD

About Us Indian Company with an International presence Turnover 09-10; Rs. 402.36 Crores, Turnover 1 HY – FY11 : 246.23 Crores Among the fastest growing Indian Companies

Ranked 24th in ORG IMS Rx Audit on MAT basis (ORG October 2010)

Complete solution provider CRAMS – R&D, Regulatory & Mfg

USFDA & MCC SA approved sterile Ophthalmic facility

UK MHRA, German Darmstad, ANVISA Brazil, MCC SA approved tablets, creams & capsules facility

R&D and Regulatory capabilities Employs 3000 people

100 R&D scientists 1700 field staff

Our Infrastructure

Corporate Office

Manufacturing Facilities

5 Formulations facilities

2 API facilities

R&D Centre

Depots & Branches

34 Branches

Domestic Marketing Network

7 divisions

PAN INDIA presence

Our Business Indian Business

Branded Generic Formulations

APIs

International Business Regulated Markets

Generics

CRAMS

APIs

Emerging Markets Branded Generic Formulations

APIs

Indian International

Indian Business

INDOCO – GP, CP, Gynaec, Life Style SPADE – GP, CP, Paediatrician WARREN –Dental, ENT EXCEL – Opthal SPERA – GP, Gynaec, Paediatrician XTEND – GPs in Extra Urban Towns ETERNA – CPs, Orthos, Gastro

International Presence

FormulationsInfrastructure

SITE DOSAGE FORM STATUSGOA I TABLETS UK MHRA, GERMAN

BRAZIL ANVISA, MCC SA, TGA

CREAMS & OINTMENTS UK MHRA

GOA II STERILE EYEDROPS US FDA, MCC SA

GOA III TABLETS UK MHRA, GERMAN

BRAZIL ANVISA, MCC SA, TGA

PILOT TABLET

CAPSULES

WALUJ TABLETS ROW

BADDI TABLETS & LIQUID ORALS SCHEDULE M

UK MHRA, TGA, Slovenian Authorities

CREAMS & OINTMENTS

TOOTHPASTES

API Infrastructure KILO PLANT

Reaction Systems: 16 to 500 L Total Reactor Volume: 1 cubic meters Temperatures range: -55 to + 150 celsius

MULTI-TON PLANT Reactor Capacity: 500 to 4000 L Total Reactor Volume: 55 cubic meters

NEW OPHTHALMIC FACILITY Reactor Capacity: 500 to 2000 L Total reactor Volume: 15 cubic meters

INTERMEDIATES FACILITY Reactor Capacity: 500 to 4000 L Total Reactor Volume: 50 cubic meters

R & D The state-of-art, stand alone, US $ 10 million R & D

center for Formulations, API & Intermediates is located at Rabale- near New Mumbai

The R & D center in a area of 70,000 Sq.feet is designed to accommodate more than 200 scientists and technical personnel

This center is equipped with all required sophisticated hardware and software

The state of art cGMP standard KILO LAB is a part of this Research Center

R & D

F&D

Regulatory

API Research

F & DNDDS

GENERICS

CONTRACT RESEARCH

CONTRACT MFG

DOMESTIC PIPELINE

Over 50 Scientists working estimated to go up to 75 next year.

Launched 12 new products during last year

Completed 20 and currently working on 19 euro dossiers, completed 3 and working on 9 ANDA projects. These are Indoco’s own IP.

Filed 9 ANDAs for various US partners. 3 Already Approved

926 Formulation Dossiers of 161 products submitted to 54 countries & 20 products are under preparation for 13 countries.

Executing contracts for Development work for International Companies. Multiple site transfer projects and Euro Dossiers completed to the satisfaction of the European Customers.

API ( R&D)CONTRACT RESEARCH

CUSTOM SYNTHESIS

GENERICS

KILO LABKILO LAB

ANALYTICALANALYTICAL IPRIPR

SCALE UPSCALE UP

SYNTHETIC CHEMISTRY

SYNTHETIC CHEMISTRY

API R&DAPI R&D

Regulatory

• 8 USDMF

• 1 DMF for Canada

• 4 EU DMF

• 5 COS

EU DMFEU DMF

COSCOS

JDMFJDMF

US DMFUS DMF

REGAFFAIRS

API

REGAFFAIRS

API

Regulatory

• Submitted 60 dossiers to various customers in Europe, New Zealand, Australia & SA

• 56 in PipelineDOSSIERSDOSSIERS CTDCTD

ANDAANDA

REG AFFAIRS

REG AFFAIRS

CRAMS

Performance Highlights

Integrated player R&D, Manufacturing & Marketing in both API &

Formulations Strong presence in India

Ranked 22nd in Rx Audit (IMS ORG-Sep 10) Ranked 31st in Retail Audit (IMS ORG-Sep 10)

Focused on exports International Sales estimated to grow more

than 35% Forging strong partnerships such as Watson &

Aspen

Analysis ofAnalysis of Profit and Loss AccountProfit and Loss Account

Rs. In LacsPARTICULARS

QUARTERLY HALF YEARLY YEARLY

Quarter Ended Sept 10

Quarter Ended Sept 09

%Growth

Half Year Ended 30.09.10

Half Year Ended 30.09.09

    %Growth

Year Ended

31.03.2010

INCOME         

SALES & OPERATIONS 13378 9630 38.9 % 24623 19555 26.0 % 40231

LESS : EXCISE (144) (87)   (251) (178) (402)

NET SALES 13234 9543 38.7 % 24372 19377 25.8 % 39829

ADD : OPERATING INCOME 310 64   459 293 490

TOTAL INCOME 13544 9607 40.9 % 24831 19670 26.2 % 40319

EXPENDITURE  

MATERIALS 6055 4073   10921 8103 17391

STAFF COST 1854 1446 3330 2740 5646

OTHER EXPENSES 3333 2553 6178 4950 10453

EBIDTA 2302 1535 50.1 % 4402 3877 13.6 % 6829

R&D EXPENSES 218 225 410 473 1022

INTEREST 53 66 118 159 291

DEPRECIATION 335 289 656 568 1210

MISC. EXP.WRITTEN OFF 1 2 2 4 9

OPERATING PROFIT 1913 1178 62.4 % 3626 3146 15.3 % 5319

PAT 1526 925 65.0% 3008 2613 15.1 % 4209

Growth Drivers

• Present domestic marketing set up• Focus on high value products such as anti

infective, GI products, etc.• Intensive Pan – India coverage of medical

fraternity through various marketing divisions.

• Partnering with Watson and Aspen• Strong R&D Set up• New Plants at Goa and Waluj

Thank you very much